UBS Maintains Neutral on Amrize, Lowers Price Target to $42

UBS analyst Julian Radlinger has maintained a Neutral rating on Amrize (NYSE: AMRZ) and has lowered the price target from $57 to $42. This adjustment reflects a change in the analyst's outlook on the company's stock performance.